Cardiome Pharma Corp. (CRME) Fundamental Analysis & Valuation

NASDAQ:CRME

Current stock price

2.33
-0.05 (-2.1%)
Last:

This CRME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

No Fundamental Analysis report for CRME not available.

CRME Fundamentals: All Metrics, Ratios and Statistics

Cardiome Pharma Corp.

NASDAQ:CRME (5/16/2018, 8:04:41 PM)

2.33

-0.05 (-2.1%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners50.49%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap81.25M
Revenue(TTM)25.35M
Net Income(TTM)-31.94M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)0%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.2
P/FCF N/A
P/OCF N/A
P/B 8.94
P/tB N/A
EV/EBITDA -4.81
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.73
BVpS0.26
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.06%
ROE -351.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -125.98%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 4.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.97
Quick Ratio 3.17
Altman-Z -9.75
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y14.44%
EPS Next 2Y22.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.5%
Revenue growth 3YN/A
Revenue growth 5Y41.24%
Sales Q2Q%25.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Cardiome Pharma Corp. / CRME Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Cardiome Pharma Corp. (CRME) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRME.


What is the valuation status of Cardiome Pharma Corp. (CRME) stock?

ChartMill assigns a valuation rating of 1 / 10 to Cardiome Pharma Corp. (CRME). This can be considered as Overvalued.


Can you provide the profitability details for Cardiome Pharma Corp.?

Cardiome Pharma Corp. (CRME) has a profitability rating of 1 / 10.


Can you provide the financial health for CRME stock?

The financial health rating of Cardiome Pharma Corp. (CRME) is 2 / 10.